Symbols

WGRX

Wellgistics·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About WGRX

Wellgistics Health, Inc.

A holding company centered on pharmaceuticals and healthcare services

Industry

Pharmaceutical

Established Date

09/06/2022

Listing Date

02/21/2025

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.wellgisticshealth.com

Security Type

Common stock

Office address

3000 Bayport Drive Suite 950 Tampa Florida 33607

Business

Introduction

Wellgistics Health, Inc., was originally incorporated on September 6, 2022 and re-incorporated in Delaware on November 15, 2022. Wellgistics Health is a holding company with existing and planned operating companies, focusing on pharmaceutical and healthcare services, operating a micro-healthcare ecosystem with a portfolio of pharmacies, wholesale businesses and technology divisions that provide platforms for hub and clinical services. The company is committed to improving the lives of patients and provides solutions for pharmacies, healthcare service providers, pharmaceutical manufacturers and payers to coordinate the acquisition, dispensing, distribution and clinical management of various treated diseases by integrating patient-centered concepts and healthcare applications.

Company Financials

EPS

WGRX has released its 2025 Q3 earnings. EPS was reported at -0.46, versus the expected 0, missing expectations. The chart below visualizes how WGRX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

WGRX has released its 2025 Q4 earnings report, with revenue of 1.67M, reflecting a YoY change of -86.54%, and net profit of -27.85M, showing a YoY change of -543.00%. The Sankey diagram below clearly presents WGRX's revenue sources and cost distribution.